emtricitabine + rilpivirine + tenofovir alafenamide

**Emtricitabine + rilpivirine + tenofovir alafenamide** is a once-daily, oral fixed-dose antiretroviral combination for treatment of human immunodeficiency virus type 1 infection. It contains emtricitabine and tenofovir alafenamide, nucleoside or nucleotide reverse transcriptase inhibitors, plus rilpivirine, a non-nucleoside reverse transcriptase inhibitor. The components act at distinct sites on HIV-1 reverse transcriptase to suppress viral replication. The originator product is marketed as **Odefsey** and is supplied as a film-coated tablet containing emtricitabine 200 mg, rilpivirine 25 mg, and tenofovir alafenamide 25 mg. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208351s014s015lbl.pdf))

Brand names

Emtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisOdefsey

Other names

emtricitabine/rilpivirine/tenofovir alafenamideFTC/RPV/TAFFTC/RPV/TAF fixed-dose combinationR/F/TAF